Pfizer Closes Hospira Acquisition; To Update 2015 Guidance - Quick Facts

(RTTNews) - Pfizer Inc. (PFE) announced it has completed acquisition of Hospira, Inc. On September 3, 2015, Hospira's common stock ceased trading on the NYSE. Pfizer said the former Hospira shareholders became entitled to receive the per share merger consideration of $90 in cash for each share of Hospira common stock they owned as of September 3, 2015. Pfizer has appointed Computershare Trust Company N.A. as paying agent for merger consideration.

Pfizer continues to expect the transaction to be immediately accretive to adjusted diluted EPS upon closing, and accretive by $0.10 - $0.12 per share in the first full year after the close, with additional accretion anticipated thereafter. Pfizer expects the transaction will deliver $800 million in annual cost synergies by 2018.

Pfizer said the company intends to update its 2015 financial guidance in the coming weeks to incorporate Hospira. The guidance will reflect the anticipated contribution from Hospira operations from the time of the completion of the Hospira merger to Pfizer's fiscal year end, which is November 30, 2015 for Pfizer's international fiscal year and December 31, 2015 for Pfizer's U.S. fiscal year.